Intraoperative radiotherapy in the conventional linear accelerator room for early breast cancer treatment: an alternative choice in developing countries.

Intraoperative radiotherapy with a single dose of electrons (ELIOT) in the conservative treatment of breast cancer is a possibility under evaluation in clinical trials. The costs of the mobile linear accelerator with a robotic arm, used in intraoperative radiotherapy, are prohibitive for poor countries. The aim of this study was to evaluate the feasibility of ELIOT in the accelerator room of the Radiotherapy Service for early breast cancer treatment. We analyzed 40 patients submitted to breast conservative surgery and ELIOT, in the accelerator room of the Radiotherapy Service at the Hospital of Pontificia Universidade Católica do Rio Grande do Sul in Brazil from January 2004 to July 2005. Patients with unifocal breast carcinoma smaller than 25 mm, aged over 45 years, who were candidates for conservative surgery were selected and a total dose of 21Gy was delivered, without further radiotherapy. In the short-term follow-up (median 18 months), six patients (15%) presented with some grade of fibrosis under the scar. One case (2.5%) of local recurrence was reported. There are no cases of contralateral carcinoma or distant metastases so far. Our data show that intraoperative radiotherapy with electrons can be safely performed in an accelerator room with a conventional machine.

Use of technetium-99m-labeled colloid albumin for preoperative and intraoperative localization of nonpalpable breast lesions.

BACKGROUND: Management of clinically occult breast lesions is still a major point of debate. Several techniques (eg, skin projection, guidewire localization) have been proposed, but all of them have technical limitations. STUDY DESIGN: The aim of this study was to assess the efficacy of a new method to locate occult breast lesions using technetium-99m (99mTc)-labeled colloid particles of human serum albumin (radioguided occult lesion localization). We studied 647 consecutive patients (mean age 51.3 years; range 25 to 77 years) with nonpalpable breast lesions detected mammographically or by ultrasonography. Within 24 hours before operation, 3.7 MBq (0.1 mCi) of 99mTc-labeled colloid was injected directly into the center of the lesion using stereotactic mammographic guidance (when only microcalcifications were present) or ultrasonographic guidance (for opacities). Excision biopsy was performed with a gamma-detecting probe. After excision, the area was checked for residual radioactivity and the specimen was radiographed to verify complete removal of the lesion. The material was then sent for pathologic examination. The absorbed dose to the inoculated area and the external irradiation to staff were also determined. RESULTS: In all 647 patients, the "hot spot" was located easily and quickly. X-ray and scintigraphy of the specimen verified the presence and centricity of the lesion in all patients but three (99.5%). Pathologic examination revealed 340 cancer lesions (52.6%). Of these patients, 339 (99.7%) were treated by breast-conserving operations and one (0.3%) received a modified radical mastectomy. No major surgical or postoperative complications were encountered. No recurrences were documented during follow-up. The absorbed dose to the breast and other tissue was negligible (0.03 +/- 0.02 mGy/MBq), as was the dose to the surgeon's hands (7.5 +/- 5.0 microSv/h). The latter dose represents 0.015% and 0.002% of the recommended limits of the European Community for the general population and for exposed workers, respectively. CONCLUSIONS: Radioguided occult lesion localization seems to offer a simple and reliable method to locate occult breast lesions with a gamma-detecting probe, allowing complete removal of the lesion in 99.5% of patients. Because of the small quantity of radioactivity, the procedure is safe for both patients and medical staff.

Identification of sentinel node in breast cancer.

Axillary lymphadenectomy is a very important procedure in the staging of breast cancer patients. However, it is associated with a significant morbidity rate. On the other hand, using early diagnosis we can see a high number of cases where the lymph nodes are negatives. With the intention of avoiding unnecessary axillary dissection, the possibility of evaluating a single node has been studied. This lymph node, defined as "sentinel node", would be the first to receive tumoral lymphatic drainage. The aim of this study is to evaluate: (i) the efficacy of the methods to identify the sentinel nodes, (ii) estimate the predictability of the histological examination of the sentinel node in comparison to other nodes of the axilla, (iii) compare the efficacy of the frozen section regarding the definitive histological examination of the same node. This study was performed in 29 patients, and the sentinel node was identified in all of them. It was metastatic in 7 (24.1%). Out of the 22 patients where the node was negative, 15 were submitted to complete dissection. Out of these 15, there was one case (6.7%) where one lymph node of the first level was positive. All 7 patients with the positive sentinel node were submitted to axillary dissection. When comparing the histological examination of the sentinel node with other nodes, we got a sensitivity of 87.5%, specificity of 100%, predictive positive value of 100%, predictive negative value of 93% and efficacy of 95%. The intra-operative examination was made in 24/29 cases (82.7%). The correlation between both examinations was 95.8%. This study shows that the technique of the sentinel node will be a reliable method to avoid radical axillary dissection in breast cancer patients with early diagnosis.